Oragenics: concussion drug ONP-002 shows no genotoxicity in animal study; Phase II planned

ORAGENICS INC

ONP-002 completed in vivo micronucleus assay; no evidence of genetic mutations or DNA damage across low, medium, high doses.
Study conducted under GLP conditions with VivoPharm; supports safety for planned Phase II clinical trial for concussion.
Company previously reported safety margin in two-species tox and cardiac safety (GLP hERG); now genotoxicity cleared.
Concussion affects ~69M annually globally; post-concussion symptoms cause long-term disability in up to 20% of patients.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.